Arriola, Edurne
de Castro, Javier
García-Campelo, Rosario
Bernárdez, Beatriz
Bernabé, Reyes
Bruna, Jordi
Dómine, Manuel
Isla, Dolores
Juan-Vidal, Óscar
López-Fernández, Teresa
Nadal, Ernest
Rodríguez-Abreu, Delvys
Vares, María
Asensio, Úrsula
García, Luis F.
Felip, Enriqueta
Funding for this research was provided by:
Pfizer
Article History
Accepted: 23 June 2024
First Online: 31 July 2024
Declarations
:
: This project was developed with funding from Pfizer.
: Edurne Arriola has received speaking and/or advisory honoraria from Pfizer, Janssen, Sanofi, AstraZeneca, Bristol Myers Squibb, Lilly, Boehringer Ingelheim, Takeda, Roche, and MSD; and travel support from Takeda, Roche, and AstraZeneca. Javier de Castro has received research funding and educational fees from AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, and Hoffmann-La Roche; honoraria or held advisory role for AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, GSK, Janssen, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Hoffmann-La Roche, Sanofi, and Takeda. Rosario García-Campelo has received research funding and grant support from Roche, Pfizer, Merck Serono, and Bristol Myers Squibb and received honoraria or held advisory role for Pfizer, Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Merck Serono, Sanofi, Lilly, Amgen, Janssen, Boehringer Ingelheim, AstraZeneca, Takeda, Regeneron, and Sanofi; and travel support from Roche, Takeda, Astra Zeneca, Roche, and MSD. Reyes Bernabé has received speaking and/or advisory honoraria from Pfizer, Janssen, Sanofi, AstraZeneca, Bristol Myers Squibb, Roche, Takeda, and Jannsen. Beatriz Bernárdez has received speaking and/or advisory honoraria from Pfizer, Janssen, Astellas, Sanofi, AstraZeneca, Bristol Myers Squibb, Merck, Daiichi Sankyo, Takeda, and MSD. Jordi Bruna has received personal consulting fees or congress travel support from Takeda, Eisai, CSL Behring, Pfizer, and Novocure. Manuel Dómine has received honoraria for advisory board/consultancy from AstraZeneca, Boehringer Ingelheim, Janssen Cilag, MSD, Pfizer, Roche, Sanofi, and Takeda; and honoraria for speaker from AstraZeneca, Bristol Myers Squibb, MSD, Pfizer, Roche, and Takeda. Dolores Isla has received honoraria and held advisory role for Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, F. Hoffmann-La Roche, Janssen, Lilly, Merck, MSD, Novartis, Pfizer, Sanofi, and Takeda. Óscar Juan received honoraria and held advisory role for Bristol Myers Squibb, Merck Sharp & Dohme, Roche/Genetech, AstraZeneca, Pfizer, Eli Lilly, Takeda, and Janssen; and travel, support from Takeda and AstraZeneca. Teresa López-Fernández has received honoraria for advisory board/speaker from Philips, Pfizer, Bristol Myers Squibb, Janssen, Daichi Sankyo, Myocardial Solutions, AstraZeneca, Beigene, and Bayer. Ernest Nadal has received research funding and grant support from Roche, Pfizer, Merck-Serono, and Bristol Myers Squibb; received honoraria or held advisory role for Pfizer, Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Merck Serono, Sanofi, Lilly, Amgen, Janssen, Daiichi-Sankyo, Boehringer Ingelheim, AstraZeneca, Qiagen, Pierre Fabre, Takeda, Regeneron, and Sanofi; and travel support from Roche, Takeda, and MSD. Delvys Rodríguez has received personal fees/honoraria for consultancy/advisory role and lectures from Roche/Genentech, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Merck Serono, Eli Lilly, Gilead, Sanofi, Regeneron, Incyte, Pfizer, Takeda, and Novartis; travel expenses from Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Sanofi, Regeneron, and Novartis; and grant support for studies from Bristol Myers Squibb. María Vares has no conflicts of interest. Úrsula Asensio was a Pfizer employee when this manuscript was written. Luis F García is a Pfizer employee. Enriqueta Felip has received personal fees/honoraria for consultancy/advisory roles and speaker bureau from AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F. Hoffmann-La Roche, Genentech, Gilead, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Peervoice, Peptomyc, Pfizer, Regeneron, Sanofi, Takeda, Touch Oncology, and Turning Point Therapeutics and has been an independent member of the board for Grifols.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: A main coordinator and other experts developed each section of this article. The metabolic and cardiovascular adverse events section was coordinated by Javier de Castro, with the expertise of Manuel Dómine, Dolores Isla, and Teresa López-Fernández. The neurological adverse events section was coordinated by Enriqueta Felip, with the expertise of Ernest Nadal, Reyes Bernabé, and Jordi Bruna. Other adverse events were coordinated by Rosario García-Campelo with the expertise of Óscar Juan-Vidal, Delvys Rodríguez-Abreu, and María Vares. The pharmacological interactions section was coordinated by Edurne Arriola with the expertise of Beatriz Bernárdez. All the authors participated in the development of the figures and tables.